Phase 2 Trial Results The Phase 2 TRIUMPH trial published data showing: Average weight loss of approximately 17.5% at 24 weeks (highest dose group) Projected weight loss exceeding 24% at 48 weeks based on trajectory Dose-dependent weight loss, higher doses produced stronger outcomes Blood sugar improvements consistent with the GLP-1 mechanism For context, tirzepatide produced approximately 2022% weight loss over 72 weeks in SURMOUNT
A double-strength cup has two scoops per cup
The 4 studies (n=481 pregnancies) comprised women with type 1 diabetes (n=366), women with type 2 diabetes (n=84), women diagnosed with overt diabetes in pregnancy (n=12) and women with insulin-requiring GDM (n=19)
Learn more about Diabetes Management
They reduce the release of cytokines like IL-1, IL-6, and TNF, upregulate the anti-inflammatory cytokine TGF-, and downregulate the expression of disease-associated microglial (DAM) genes, ultimately enhancing A clearance [74]